Boehringer Ingelheim International GmbH;Boehringer Ingelheim Pharma GmbH & Co. KG
发明人:
申请号：
EP16152228.9
公开号：
EP3037095A2
申请日:
2007.11.08
申请国别(地区):
EP
年份:
2016
代理人:
摘要：
The present invention is directed to a pharmaceutical composition comprised of one or more SGLT-2 inhibitor compound(s) in combination with one or more therapeutic agents which is suitable for the treatment of metabolic disorders including type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance, hyperglycemia, postprandial hyperglycemia, overweight, obesity, including class I obesity, class II obesity, class III obesity, visceral obesity and abdominal obesity, and metabolic syndrome.
